Directory of Peptide API Manufacturing Plants

Wuhan Vanz Pharm Inc.), located in Wuhan, Hubei Province, was established in 2011 (some B2B files are recorded as 2016). It is a API (API), pharmaceutical intermediates, fine chemicals, peptides and food additives that integrate R&D, production and sales. Its products are sold worldwide. The company has a R&D center of about 1000 square meters in Wuhan (including multiple synthesis laboratories, pilot amplification laboratories and analytical laboratories). The manufacturing base is equipped with 100L-5000L reactors, which can provide one-stop services from R&D to commercial production. With long-term cooperation from Shanghai Institute of Organic Chemistry and Wuhan University, it has completed more than 20 APIs and intermediates R&D. Business covers custom synthesis (CDMO/CMC orientation), API contract production, quality control and regulatory consulting. Note: The company uses small molecule APIs/intermediates and custom synthesis as its core business, and peptides is only one of its product categories, not a dedicated peptide API factory.

Chongqing Zhixia Chemical Co., Ltd. (related to Nanjing Chenruisheng Biomedical Technology) was established in September 2023. It is a small and micro enterprise, mainly engaged in the research and development and supply of polypeptide GLP-1 raw materials, representing products including Semaglutide, Tirzepatide and other polypeptide raw materials. The business model is factory, customization and service, and the products are mostly marked as "for scientific research or export only". The company announced a registered capital of 500,000 yuan, 10–50 employees, and an annual turnover of about 3-5 million yuan. The contact information is shared with Nanjing Chen Ruisheng (the same phone/email address), and is positioned as a peptide small molecule GLP-1 raw material supplier for the global scientific research and export market.

Shenzhen Peptide Chuangsheng Technology Co., Ltd. is a pioneer supplier of high-quality active peptides (cosmetic peptides) based in Shenzhen and radiating the world. It focuses on molecular biology and AI-driven peptide structure-activity research to provide efficient, verifiable and sustainable active peptide raw material solutions for scientific research institutions, pharmaceutical groups, medical cosmetic institutions and functional skin care brands. It has a Peptide AI design system and a peptide professional-grade laboratory, with a raw material purity of 99.8% pharmaceutical grade, adopts a biological + chemical synthesis green process (zero solvent instead of DMF), and a transdermal rate of > 80%, which meets the EU ECOCERT, US FDA gras, Japan JHOSPA and other regulations; and provides customized peptide synthesis (minimum order of 100g, 3–6 weeks delivery). The product covers 100 cosmetic peptides with 9 major efficacy matrices (blue copper peptide GHK-Cu, acetylhexapeptide-8/aquirelin, palmitoyl pentapeptide-4, conopeptide, etc.), 100% made in China, and serves 100 + customers worldwide (European pharmaceutical giant, North American pure beauty brand, CJK head beauty group).

Sichuan Ampelbo Biotechnology Co., Ltd. (Chengdu Boke Pharmaceutical Technology Co., Ltd., Chengdu) is a professional R&D, production and sales of amino acid derivatives (amino alcohols, amino aldehydes, N-methyl amino acids, amino acid tert-butyl esters, Boc/Fmoc/Cbz protected amino acids, benzyl esters, amino acid amides, etc.). It also provides polypeptides, piperidine derivatives and chiral amine series products. It can provide domestic and foreign customers with high-quality pharmaceutical intermediates and fine chemicals from grams, kilograms to tons. Its products are exported to Europe and North America. It is a small high-tech/trade-oriented enterprise (with a staff size of about 8–50 people). The polypeptide is one of its product lines, with a partial amino acid protecting group and a polypeptide side chain/intermediate direction.

Nanjing Yuanpeptide Biotechnology Co., Ltd. (Yuanpeptide Biotechnology) was established in 2018 and is located in the Biomedical Valley/Zhongdan Ecological Life Science Industrial Park in Jiangbei New District of Nanjing. It is a science and technology-based small and medium-sized enterprise (selected as a science and technology-based small and medium-sized enterprise in Jiangsu Province in 2025) that focuses on the synthesis of scientific research peptides and customized services. The company has 46 employees, an independent research and development center and 900 square meters of sterile laboratory, 4 standardized peptide production lines, equipped with Waters LC-MS/MS, UPLC, automatic purification system, automatic lyophilization system and other precision instruments, with a peak monthly production capacity of about 3000 peptides. Stable synthesis of conventional linear peptides and 60 amino acid long peptides, 100 amino acid super long peptides, specializing in polydithiocyclic peptides, head and tail closed-loop peptides, book peptides, highly hydrophobic membrane penetrating peptides, D-type amino acid peptides, glycopeptides, lipopeptides and other complex structures; modified types cover phosphorylation, sulfonation, methylation, acetylation, pegylation, biotin labels, a variety of fluorescent labels (FITC/Cy series), isotope labels (13c/15N), protein cross-linking and more than 300 kinds. Service ranges from milligrams to kilograms, and long-term cooperation with universities and medical institutions such as Nanjing University, Fudan, Shanghai Jiaotong University, and West China Hospital.

Hefei HeSheng Biotechnology Co., Ltd. was established in 2014 and is located in Hefei High-tech Zone. It is an innovative polypeptide biotechnology company with polypeptide technology as its core. It focuses on the customization, research and development, production and service of polypeptide-related products, and is committed to becoming an international polypeptide CRDMO integrating polypeptide scientific research and customization, drug polypeptide intermediates and impurity customization, peptide API production, drug polypeptide research and development and process development, and beauty polypeptide research and development and production. The factory area of the company is about 4,000 square meters, and there are polypeptide R&D and production workshops such as synthesis, purification and analysis, with a total planned annual raw material production capacity of 200 kg (powder). It has more than 100 patents (including 24 invention patents). The service covers research custom polypeptide synthesis (long peptide, difficult peptide, branch peptide), labeling (isotope, fluorescence), cyclic peptide (amide ring, disulfide ring, subscription peptide ring, thioether ring), modification (glycopeptide, phosphorylation, peg, etc.), deuterated service, and polypeptide drug impurity customization; GMP small test/pilot and amplification production (mg to kg grade) can be carried out.

Founded in 2013 in Hefei, Cellmano Biotech Limited is a high-tech company focused on the research and industrialization of solid phase peptide synthesis methods. The company has been engaged in the R&D and manufacturing of solid-phase polypeptide synthesis since 2011. It has a R&D center that meets the requirements of solid-phase synthesis, lyophilization and purification, and a complete set of analytical and testing instruments. The synthesis records, purification methods and test reports of each batch of products are archived in detail. Its main business includes peptide intermediates, cosmetic peptides (cosmetic peptides), custom synthesis of peptides, and peptide CMO services. It can provide customized peptides from mg to kg, from crude to 98% purity, and establish more than 2,000 commonly used catalog peptides in stock (gradually improve inventory, deliver in as fast as one week) to serve customers around the world. Approximately 10–50 employees.

Harbin Jixianglong Biotechnology Co., Ltd. was established at the end of 2011 and is located in the Harbin Limin Development Zone. It covers an area of 23,000 square meters, 16,000 square meters of buildings, a registered capital of 18.31 million yuan, a net asset of 110 million yuan, and 260 employees (70 R&D). It is a national high-tech enterprise, Heilongjiang Specialized New SME and Synthetic Peptide Drug Technology Innovation Center. The company focuses on independent R&D and custom R&D and production of peptide drugs, forming a two-wheel drive pattern of peptide raw material sales and formulation R&D services (CRO). It has built a GMP-certified peptide raw material production workshop, equipped with more than 300 sets of equipment such as solid phase synthesizers, preparation liquid chromatography, lyophilizers, and HPLC. The company has a complete industrial chain of R&D, approval and production, and has obtained 10 API production approvals (the third in the country in terms of quantity) using its own technology; Smeglutide and Tirpotide have completed US DMF filings with the US FDA and obtained NDCs for sale in US pharmacies; it has 16 invention patents (including 5 compound patents).

Sinopep-Allsino Biopharmaceutical is a global supplier of commercial grade APIs and a full range of polypeptide/oligonucleotide CDMOs. Providing end-to-end CMC development and cGMP production from early R&D to commercialization for new drugs (NCE) and innovative pharmaceutical companies since 2009. The company's current production capacity of polypeptides is about 20–30 tons/year. It has built a large-scale GMP oligonucleotide (ASO, siRNA and GalNAc, AOC, liposome and other conjugates) production facility that can produce thousands of kilograms per year in Lianyungang, Jiangsu Province. At the same time, it has small molecule generic drugs and NCE commercial production capacity. The quality and regulatory system is mature. It has passed four FDA on-site inspections, strictly follows FDA and ich guidelines, and provides process development, analytical method development and verification, stability research, and global IND/NDA declaration support.